Can secukinumab treat ankylosing spondylitis?

Secukinumab is the first biologic treatment to treat ankylosing spondylitis (AS) by specifically targeting and blocking IL-17A, one of several molecules thought to play a role in causing inflammation. It has been approved in several countries, including the United States and the European Union, and has been shown to help reduce the symptoms of ankylosing spondylitis(AS). The benefits of secukinumab are generally seen and persist with long-term treatment (up to 5 years) regardless of whether patients have previously received tumor necrosis factor (TNF) inhibitor therapy.

Ankylosing spondylitis(AS) is a chronic autoimmune inflammatory disease that primarily affects the axial skeleton. Typical symptoms include chronic back pain, stiffness, and progressive loss of spinal mobility. If not properly treated, ankylosing spondylitis can lead to severe disability (including complete fusion of the axial skeleton) and impaired quality of life (QOL), and NSAIDs are the recommended first-line treatment for active ankylosing spondylitis. Tolerability of secukinumab in patients with ankylosing spondylitis was consistent with that in patients with plaque psoriasis.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.